Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage

Stopped early · Phase 3

Conditions studied: Subarachnoid Hemorrhage, Aneurysmal

In brief

The purpose of this research is to compare patients with aneurysmal subarachnoid hemorrhage on dexmedetomidine compared to propofol to assess if one group has decreased inflammation. The investigators hypothesis is that the group assigned to receive dexmedetomidine will have a more profound decrease in markers of inflammation over time.

Key facts

Study ID

NCT01565590

Run by

University of Cincinnati

People needed

4

Starts

2012-02-01

Expected to finish

2015-07-01

Last updated by the study team

2018-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aneurysmal subarachnoid hemorrhage
• World Federation of Neurological Surgeons (WFNS) grade 4-5 (see table below)
• Surgical intervention with clip or coil
• Placement of cerebrospinal fluid drain (lumbar or ventricular)
• Mechanically ventilated at start of infusion

You may not qualify if…

• Hemodynamic instability (SBP < 100, HR <60, or on continuous infusion of catecholamines) at screening
• Heart failure class III or IV (New York Heart Association)
• Renal failure (RIFLE classification - see table below)
• Liver failure (serum protein < 3 g/dL and total bilirubin > 5 mg/dL)
• Known or suspected brain death
• Pregnancy
• Unable to receive dexmedetomidine within 48 hours of injury and 4 hours of surgery
• Allergy to dexmedetomidine
• Prisoners

Where it is running

• University Hospital — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.